INVION LIMITED — AGM Information 2015

Nov 17, 2015

ASX ANNOUNCEMENT

==> picture [161 x 76] intentionally omitted <==

INVION LIMITED AGM: CHAIR’S ADDRESS & CEO PRESENTATION

Brisbane, Australia and Delaware, United States, 18 November 2015: Invion Limited (ASX: IVX) is pleased to provide the Chair’s Address and CEO presentation to the 2015 Annual General Meeting of Shareholders being held today at 2.00pm (AEST) at the offices of McCullough Robertson Lawyers, Level 11, 66 Eagle Street Brisbane.

Address to Shareholders by Mr Brett Heading, Chair of the Board of Directors

As shareholders will know from recent announcements and other communications, 2015 has seen your company deliver against major strategic and clinical development milestones.

Managing Director and CEO, Dr Greg Collier, will shortly speak in detail about the status of the company’s pipeline, however I am pleased to stand before you today and report, that with three drug assets across four development programs, Invion has achieved major milestones this year including:

1. confirming pre-IND status for inhaled INV102 (nadolol) as a potential therapy for asthma, COPD & cystic fibrosis and the commencement of toxicology studies for that strategy;

2. the completion of the phase 2 clinical trial of INV103 (ala-Cpn10) in lupus patients;

3. the selection of formulation and a device for inhaled INV104 (zafirlukast) and the commencement of manufacturing for toxicology and clinical supplies for that program;

4. and most significantly, the completion of the 155-patient Phase 2 smoking cessation trial which reported positive safety and efficacy data in October.

In summary, the Phase 2 smoking cessation data demonstrated that treated patients receiving INV102 (nadolol) were more likely to stop smoking completely or dramatically reduce the number of cigarettes smoked than untreated patients.

We believe this is highly positive data for the company and validates management’s clinical development strategy. It also places the company in a good position for the achievement of another major milestone – which is an End of Phase 2 Meeting with the US FDA on this program.

These are not insignificant achievements for a company of Invion’s size and operating budget.

Invion Limited ABN 76 094 730 417 GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com

ASX ANNOUNCEMENT

==> picture [161 x 76] intentionally omitted <==

The overarching goal of activities in 2015 has been to enhance the value of the company’s assets by continuing to mitigate risk along each program’s development pathway, and to realise the potential of those assets.

To this end, the corporate and business strategy has been focused on identifying and developing potential partners, and Dr Collier will give an update on the status of these discussions.

In the coming 12 months therefore, we anticipate significant changes in the company’s structure, which may come in the form of a strategic cornerstone investment, or merger, sale or out-licence of Invion’s intellectual property.

To support this current stage, and to provide shareholders the opportunity to take advantage of current market conditions, on 10 November the company announced a Share Purchase Plan which enables eligible shareholders to purchase additional Invion shares with no transaction or brokerage fees, and at a discount to market price. If you have not done so already, I would encourage you to read the SPP documentation carefully before the offer closes on 30 November. We are also here today to answer any questions you may have on the offer.

In relation to the company’s recent placement, there have been some concerns raised on certain options to be issued pursuant to the placement which I would like to address.

The agreement to issue the options was undertaken pursuant to a capital raising which was on the most favorable terms available to the company at the time.

Because the company did not have available placement capacity at that time, it was necessary to make the issue of options subject to shareholder approval for the purposes of Listing Rule 7.1. However, to secure the investment, the placement agreement included a restriction on the company’s ability to issue further securities if shareholders did not approve the issue of the options. The specific provision is set out below:

“Second Tranche Options will be issued promptly following the EGM, and in any event within 1 business day from the date of the EGM. If any of the Options Resolutions is not passed at the EGM, the Company will not issue securities in the Company other than Second Tranche Options until all the Second Tranche Options are placed as agreed. The Company will not be in breach of this Agreement if any Option Resolution is not passed at the EGM.”

In the circumstances, then irrespective of the outcome of the resolutions at this meeting the board intends, in the best interests of the company, to proceed with the options issue in order to fulfill the obligation under the placement agreement and to enable the Share Purchase Plan and any other share placement that may be required to proceed.

Invion Limited ABN 76 094 730 417

GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com

ASX ANNOUNCEMENT

==> picture [161 x 76] intentionally omitted <==

Lastly, it is appropriate I note the recent decision of the High Court of Australia in relation to the litigation against former directors of the company.

In June 2014, the Supreme Court of Queensland determined that the defendants in the litigation be required to repay the sum of $1,071,482, plus interest and costs, to the company. In July 2014, the Company advised that the defendants had lodged a notice of appeal against the decision. The appeal was heard by the Queensland Court of Appeal on 23 February 2015, and was dismissed with costs on 12 June 2015. The defendants (appellants) subsequently sought leave to appeal the Appeal Court decision to the High Court.

Earlier this month, the High Court dismissed the process without the need for a hearing.

The Board has always, and continues to, stand firm in its commitment to bring the matter to resolution as swiftly as possible, and intends to use all avenues available to it to recover the judgment debt, which now exceeds $1.3 million.

Before closing, I take this opportunity to thank my colleagues on the Board, and the management and the staff of Invion.

I also thank you, our shareholders, for your continued interest and active participation in Invion.

*

About Invion Limited

Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory and autoimmune disease. Invion has three drug assets in development across four development programs. INV102 (nadolol) is a beta adrenergic biased ligand targeted to reverse mucous metaplasia in the airway epithelium treat chronic inflammatory airway diseases. In Q4 2015, Invion reported that data from a 155 patient phase 2 study of oral INV102 in smoking cessation demonstrated good safety and that treated patients were more likely to stop smoking completely or dramatically reduce the number of cigarettes smoked. Feasibility for an inhaled version of the drug to potentially treat COPD and cystic fibrosis is well-progressed with 3M Drug Delivery Systems, and toxicological studies have commenced. In addition, a phase 2 study of oral INV102 in mild asthma patients funded by the US NIH is fully recruited and will complete dosing in 1H 2016. INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. An FDA-approved oral therapy, Invion is, through a joint development and licensing agreement with Hovione Scientia Limited, developing a proprietary dry powder formulation of the drug for the development of INV104 (zafirlukast) as a potential inhaled therapy for asthma. INV103 (ala-Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion reported final data from its phase 2 clinical trial in lupus patients in Q3 2015. 30mg and 100mg iv twice weekly showed reduced response to stimulation by LPS after 1 month of dosing. These data, which reflect relevant activity at the target cell type in patients with a target (autoimmune) disease, has formed the foundation of partnering discussions for this program. Invion is an ASX listed company (ASX:IVX), with operations in Brisbane, Australia and Delaware, USA.

Invion Limited ABN 76 094 730 417

GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com

CEO Presentation to AGM 18 November | 2015

Invion Limited (ASX:IVX)

Clinical-stage life sciences company targeting chronic inflammation

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited ACN 094 730 417 ( Company ). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Accordingly, neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change.

Assets in development

Respiratory

1. INV102 (nadolol) : beta blocker being targeted to treat chronic inflammatory airway diseases (e.g. asthma and COPD). Oral INV102 is also being studied as an aid to smoking cessation.

• Phase 2 completed:

  • proof of concept in biased ligand activity

  • clinically efficacious in Smoking reduction and cessation

2. INV104 (zafirlukast ): leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways and the build-up of mucus in the lungs

Risk mitigated program including prior clinical proof of concept

• Development and manufacturing collaboration with Hovione

Autoimmune

3. INV103 (ala-Cpn10) : modified naturally occurring human protein hypothesised to maintain and restore immune homeostasis

Phase 2 data completed, partnering discussions underway

==> picture [98 x 41] intentionally omitted <==

2

==> picture [328 x 282] intentionally omitted <==

==> picture [314 x 358] intentionally omitted <==

==> picture [276 x 163] intentionally omitted <==

3

STOP PRESS: Invion successfully completes Phase 2 study of INV102 (nadolol) to aid smoking cessation

Data announced 5 October 2015:

• Completed Phase 2 trial data demonstrates INV102 treated smokers were more likely to stop smoking completely or dramatically reduce the number of cigarettes smoked

• Data demonstrates that INV102 is a safe and effective treatment for patients with chronic bronchitis who are enrolled in smoking cessation programs

• Invion is preparing an End of Phase 2 Meeting request to submit to the FDA during Q4 2015

• New data paves the way for INV102 to be developed as a novel inhaled treatment for chronic airway diseases including asthma, COPD and cystic fibrosis

4

Milestone update: achievements in 2015

3 drug assets in 3 phase 2 clinical trials across 4 development programs

• Blind-broken interim data from phase 2 smoking cessation trial of INV102 (nadolol)

• Pre-IND status for inhaled INV102 (nadolol) as a potential therapy for asthma, COPD & cystic fibrosis

• Manufacture of toxicology and clinical supplies and commencement of toxicology studies for inhaled INV102 (nadolol)

• Completion of phase 2 clinical trial of INV103 (ala-Cpn10) in lupus patients

• Data from phase 2 clinical trial of INV013 (ala-Cpn10) in lupus patients

• Selection of formulation and device for inhaled INV104 (zafirlukast)

• Commencement of manufacture of toxicology and clinical supplies for INV104 (zafirlukast)

• Completion of dosing in phase 2 smoking cessation trial of INV102 (nadolol)

• Positive safety and efficacy data from phase 2 oral INV102 (nadolol) study in patients undergoing

• smoking cessation

• Completion of enrolment of NIH-funded phase 2 study of INV102 (nadolol) in asthma patients

==> picture [98 x 41] intentionally omitted <==

5

Pipeline: 4Q 2014

Oral INV102 (nadolol)

Smoking cessation Asthma

==> picture [436 x 129] intentionally omitted <==

----- Start of picture text -----

Research Formulation Toxicology Phase 1 Phase 2 EOP2 Phase 3
development and
clinical feasibility
NIH funded
………….. ………….. ………….. ………….. ………….. …………..
----- End of picture text -----

Inhaled INV102 (nadolol)

Asthma COPD Cystic Fibrosis

==> picture [140 x 94] intentionally omitted <==

Inhaled INV104 (zafirlukast)

Asthma

INV103 (ala-Cpn10)

Lupus (SLE)

6

Pipeline: 4Q 2015

==> picture [699 x 166] intentionally omitted <==

----- Start of picture text -----

Research Formulation Toxicology Phase 1 Phase 2 EOP2 Phase 3 Next milestone
development and
clinical feasibility
Oral INV102 (nadolol)
EOP2 Meeting
Smoking cessation P3 planning
Enrolment complete,
Asthma NIH funded
Reporting 2016
Inhaled INV102 (nadolol)
………….. ………….. ………….. ………….. ………….. …………..
----- End of picture text -----

==> picture [89 x 95] intentionally omitted <==

----- Start of picture text -----

Pre-IND status
achieved 1Q15
Tox and clinical
supplies manufacture
underway
Tox studies
commenced
----- End of picture text -----

==> picture [209 x 94] intentionally omitted <==

Asthma COPD Cystic Fibrosis

Inhaled INV104 (zafirlukast) Asthma partnered with Hovione

==> picture [120 x 30] intentionally omitted <==

----- Start of picture text -----

Commencement of tox
studies
----- End of picture text -----

INV103 (ala-Cpn10)

Lupus (SLE)

==> picture [123 x 68] intentionally omitted <==

----- Start of picture text -----

Partnering
----- End of picture text -----

7

==> picture [227 x 96] intentionally omitted <==

Targeting chronic inflammatory airway disease INV102 (nadolol)

Treating the airway: background and rationale

Existing drugs do an excellent job in opening constricted airways: bronchodilators include b -adrenergic and anti-muscarinic drug classes

Existing drugs do an excellent job in decreasing inflammatory cells in the airway: inhaled corticosteroid (ICS) and anti-IL5 monoclonal antibody drug classes

Fixed combinations of b agonists and ICS are the mainstay treatment of airway disease: e.g. SYMBICORT® and ADVAIR® and DULERA®

However: these drugs have had NO positive impact on death due to chronic airway disease; death is due to increased and abnormal mucus

==> picture [98 x 41] intentionally omitted <==

9

The “vicious cycle” of chronic inflammatory airway disease

==> picture [717 x 442] intentionally omitted <==

----- Start of picture text -----

Inflammation from:
-
cigarette smoke Increased
-
chronic infection (C.F.)
IL-8 and
-
allergen, O3 (asthma) beta-
arrestin
pathway
+
activity
Increased
goblet cell
Changes in production/
basal cell loss of
populations ciliated
epithelial
cells
Normal Histology
Increased mucin
damage clearance
from
abnormal
inflammatory
mucins
cells /
Increased
infection total mucus
recruitment
of
inflammatory
cells
(PMN/EOS)
Mucous metaplasia found in
COPD, asthma and CF
----- End of picture text -----

==> picture [69 x 28] intentionally omitted <==

10

The critical role of the epithelium in severe airway disease

Normal respiratory epithelium

==> picture [286 x 187] intentionally omitted <==

Severe asthma

==> picture [246 x 189] intentionally omitted <==

Chronic bronchitis

==> picture [292 x 177] intentionally omitted <==

Cystic Fibrosis

==> picture [319 x 188] intentionally omitted <==

11

Mucus causes death due to asthma, COPD and cystic fibrosis

==> picture [590 x 327] intentionally omitted <==

----- Start of picture text -----

Mucus plug
in bronchus
----- End of picture text -----

Autopsy slide from 8 year old girl with fatal asthma. Mucus is increased AND abnormal.

==> picture [98 x 41] intentionally omitted <==

12

Smoking cessation, COPD and chronic airway disease: market size and interconnectedness

==> picture [720 x 363] intentionally omitted <==

13

Oral or inhaled nadolol reverses epithelial changes and decreases inflammatory cytokines

==> picture [226 x 253] intentionally omitted <==

Control lung tissue

==> picture [227 x 253] intentionally omitted <==

Lung tissue of ‘asthmatic’ mice: epithelial cells have been converted to mucusproducing goblet cells. No effect of alprenolol.

==> picture [227 x 253] intentionally omitted <==

Lung tissue of ‘asthmatic’ mice treated with INV102 (nadolol) for 28 days: restored epithelium

References: Nguyen LP., et.al., 2011. Complementary anti-inflammatory effects of a β-blocker and a corticosteroid in an asthma model. Arch Pharmacol. 2011: Oct 2; Nguyen, LP, et al. (2008). Am J Respir Cell Mol Biol 38:256-262

==> picture [98 x 41] intentionally omitted <==

14

INV102 reverses epithelial changes via inhibition of the beta-arrestin pathway in b2 airway receptors

==> picture [678 x 335] intentionally omitted <==

----- Start of picture text -----

ligand LABA ligand INV102
Newly discovered pathway ~2000
The canonical cAMP-dependent (R. Lefkowitz)
pathway
Adenylyl cyclase Beta-arrestin Adenylyl cyclase Beta-arrestin
Asthma phenotype
Restored
epithilium
----- End of picture text -----

==> picture [69 x 28] intentionally omitted <==

15

==> picture [717 x 475] intentionally omitted <==

----- Start of picture text -----

INV102
(nadolol) DECREASED
IL-8 and
beta-
arrestin
+
pathway
activity
DECREASED
goblet cell
Restoration
production/
of ciliated
loss of
epithelial
ciliated
cells
Mucous metaplasia found in epithelial
COPD, asthma and CF cells
DECREASED mucin
damage clearance
from
abnormal
inflammatory mucins
cells /
DECREASED
infection total mucus
recruitment
of
inflammatory
Normal Histology cells
(PMN/EOS)
16
----- End of picture text -----

INV102: Phase 2 smoking cessation trial design

==> picture [636 x 324] intentionally omitted <==

----- Start of picture text -----

INCLUSION ORAL DOSING WASHOUT ENDPOINTS
11-15wks 2wks
Randomised
Primary
(IWRS) Nadolol Treatment (n=78) % Decrease in # of
Controlled
3-7wks titration &
cigarettes per day
Clinical Trial
8wks maintenance
during last 14 days
Safety
Change in FEV1,
N=155
Placebo Control (n=77) exacerbations,
Failed to quit adverse events
titration & maintenance
and
chronic cough
----- End of picture text -----

==> picture [48 x 54] intentionally omitted <==

Trial conducted under Invion-sponsored IND with the the FDA Division of Anesthesia, Analgesia and Addiction Products (DAAAP). Principal Investigator: Mario Castro, MD (Washington University)

==> picture [98 x 41] intentionally omitted <==

17

Phase 2 data strong confirmation of Invion’s strategy

Invion hypothesis

Demonstrated in Phase 2 trial

Proprietary titration scheme safe and enables subjects to reach efficacious doses of drug - no need for rescue medication

Trial subjects treated with INV102 were more likely to achieve abstinence at the conclusion of dosing (12/62, 19.3%) compared to those administered placebo (7/59, 11%)

INV102 therapy will lead to reduction in cigarettes smoked

INV102 therapy will lead to complete abstinence in some subjects

INV102 (nadolol) inhibits the beta arrestin pathway – a cellular pathway necessary for the activation of mucous metaplasia in the airway

More patients treated with INV102 achieved a >70% reduction in cigarettes smoked compared with placebo treated patients (38/62, 61% on INV102 and 21/59, 36% on placebo)

MUC5AC levels were reduced by 82% in INV102 treated patients, compared to 54% in placebo subjects. ERK1 levels were reduced by 47% for INV102 compared with 27% for placebo

==> picture [98 x 41] intentionally omitted <==

18

Leveraging the data: upcoming analysis and reporting

Data reported 5 October 2015

Ongoing analysis 4Q 2015

• Report on effects of nadolol vs placebo on key biomarkers

• ERK1/2 (beta arrestin pathway)

• MUC 5AC (abnormal mucus)

• Report on smoking cessation rates in nadolol treatment versus placebo

• Secondary analyis is on reduction versus cessation rates

• Correlation of smoking cessation/ reduction data with baseline biomarkers

• Correlation of smoking cessation/ reduction data with biomarker changes

• New IP prosecution

• Secondary analysis of responders and biomarker changes - identifying markers that are/are not useful in longer term studies

• Dose responses and responders as a function of dose, titration and history

==> picture [98 x 41] intentionally omitted <==

19

Forward strategy: progress on 3 routes to a new class of airway-specific therapy

Phase 2 data validates Invion approach for directly treating the airway epithelium even in the face of ongoing insult, such as cigarette smoking

1. Oral INV102 in smoking cessation is Invion’s “short path to market strategy”.

2. Invion proposing End of Phase 2 meeting to be convened early in 2016

3. Phase 3 Program design ready for H2 2016

2. Inhaled INV102

• Data validates development plan and pathway for inhaled INV102 for asthma, COPD and cystic fibrosis where there is a substantial unmet medical need and commercial opportunity.

• Finalizing collaboration to design new chemical entity (NCE) that is a biased ligand and inverse agonist at the b2 receptor in the epithelium

==> picture [98 x 41] intentionally omitted <==

20

Inhaled nadolol program: progress and clinical development strategy

Clinical benefits

• Once daily dosing directly to the site of injury at 1/100 of the oral dose to mitigate systemic side effects

• Targeted for long term use in COPD, severe asthma and cystic fibrosis as an add-on to existing therapies to make them safer and more effective by reducing mucous production an enabling lung healing

• Medium-term development: combination therapies

• inhaled nadolol + ICS (Asthma)

• inhaled nadolol + LAMA or LABA (COPD)

• inhaled nadolol + antibiotics (CF)

Status of collaboration with 3M Drug Delivery systems for proprietary formulation and device using 3M’s pressurised metered dose inhalation (pMDI) technology

• Formulation and device selected

• Toxicology supplies manufactured

• Clinical supplies manufactured

• Toxicology supplies provided to CRL (Montreal QUE); toxicology studies have commenced

Development program

• Pre-IND status with FDA

• Commencement of toxicology studies

• IND submission (2016*)

• Phase 1 and Phase 2 clinical studies in asthma, COPD and cystic fibrosis (2016-7*)

*The information above (and where reflected elsewhere in this presentation) sets out indicative timeframes and assumes: Invion will continue to obtain the full benefit of the available R&D tax incentive for its eligible R&D activities and clinical trials; the studies will proceed based on budgeted costs, assuming normal patient recruitment and clinical trial timelines, and with no material regulatory hurdles; and ordinary R&D expenditure will continue broadly at the same levels as for past financial years

==> picture [98 x 41] intentionally omitted <==

21

==> picture [227 x 96] intentionally omitted <==

INV104 (zafirlukast) Target: a novel inhaled non-steroidal anti-inflammatory treatment for asthma

Target: an inhaled reformulation of a successful oral therapeutic for asthma Oral Inhaled

Oral Inhaled Forms Form

Risk of neuropsychiatric/suicide ideation events? Risk of liver toxicity ? Greater efficacy due to higher airway concentrations

==> picture [35 x 71] intentionally omitted <==

Potential for once a day dosing ? Potential for expanded exercise induced bronchospasm (EIB) claims ? Rapid onset-of-action for prophylaxis ? Potential claim to reduce use of Steroids/ LABA ? Potential claim for use in children >5 years ? Combination with ICS for anti-inflammatory effect?

Singulair Prevention Only

23

FDA pre-IND established framework for reformulation of zafirlukast

Agreement reached with FDA on:

• chemistry manufacturing and controls (GMP)

• active pharmaceutical ingredient (API) with drug master file (DMF)

• formulation: dry powder inhaler (DPI) approved for development

• toxicology and bioanalytical assay (GLP) to support 4 weeks’ dosing

• 2 species for 28 days: naso-pulmonary exposure

• 1 species for 6 months

> IND submission and clinical program

• phase 1: single rising dose study for safety (paradoxical bronchoconstriction) and pharmacokinetics

• phase 1: multiple dose safety study for safety (paradoxical bronchoconstriction) and pharmacokinetics

• phase 2: challenges to reprise previous studies: cold air, exercise and allergen [cat and ragweed]; steady state dosing for signs and symptoms of asthma [diary card] and attenuation of response to exercise and/or allergen

==> picture [98 x 41] intentionally omitted <==

24

About Hovione and the XCaps inhaler

• International company with over 50 years’ experience in the development and compliant manufacture of active pharmaceutical ingredients and drug product intermediates

• With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets

• In the inhalation area, Hovione is the only independent company offering such a broad range of services.

==> picture [308 x 231] intentionally omitted <==

POWDAIR® is a patent protected device filed and granted in over 40 countries, including US (US 8677992) and EU (EP 2546460). POWDAIR® device is simple, reusable and low-cost. This DPI is indicated for applications where a chronic or a medium term acute capsule based delivery of an API is needed.

==> picture [98 x 41] intentionally omitted <==

25

==> picture [227 x 96] intentionally omitted <==

Targeting chronic inflammation caused by autoimmune disease INV103 (ala-Cpn10)

INV103 (ala-Cpn10): background and rationale

• Minimally modified form of naturally occurring protein

• Maintains heptameric structure and function

• Intracellular function: prevent protein misfolding

• Extracellular function: Cpn10 proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family (Shields et al, Clin Exp Immunol, 2011, 165: 292-300) a critical component of prevention of autoimmunity

• Significant clinical data base > 250 patients

• demonstrated anti-inflammatory and immunoregulatory activity in multiple indications including RA, psoriasis

• Strong pre-clinical data in lupus animal model (3 studies)

• reduced renal and circulating levels of key pro-inflammatory mediators (TNF-α, IL-6 and MCP-1) reduced CD4+ T cells and auto-reactive T cells and increased the number of activated DC (critical in the establishment of self tolerance)

• Toxicology support through 3 months’ dosing

• Intellectual Property position: composition of matter protection in all major markets (US 2026)

==> picture [98 x 41] intentionally omitted <==

27

INV103 (ala-Cpn10): phase 2 lupus data

• Three sets of data were reviewed from subjects who received twice-weekly doses of 10, 30 or 100mg of ala-Cpn10, or placebo

• INV103 (ala-Cpn10) well tolerated at 3 and 10 times previous highest dose

• 10mg iv twice weekly showed no effect on stimulated peripheral blood mononuclear cells (PBMC) production of 3 key cytokines (IL-1Beta, IL-6 and TNF-alpha) at 1 month of dosing

• In contrast, 30mg and 100mg iv twice weekly showed reduced response to stimulation by LPS after 1 month of dosing

• These data reflect relevant activity at the target cell type in patients with a target (autoimmune) disease

• Extending these findings will require a partner. Data is now being provided to pharma groups with a view to partnering the program

==> picture [98 x 41] intentionally omitted <==

28

Milestone update: achievements in 2015

3 drug assets in 3 phase 2 clinical trials across 4 development programs

• Blind-broken interim data from phase 2 smoking cessation trial of INV102 (nadolol)

• Pre-IND status for inhaled INV102 (nadolol) as a potential therapy for asthma, COPD & cystic fibrosis

• Manufacture of toxicology and clinical supplies and commencement of toxicology studies for inhaled INV102 (nadolol)

• Completion of phase 2 clinical trial of INV103 (ala-Cpn10) in lupus patients

• Data from phase 2 clinical trial of INV013 (ala-Cpn10) in lupus patients

• Selection of formulation and device for inhaled INV104 (zafirlukast)

• Commencement of manufacture of toxicology and clinical supplies for INV104 (zafirlukast)

• Completion of dosing in phase 2 smoking cessation trial of INV102 (nadolol)

• Positive safety and efficacy data from phase 2 oral INV102 (nadolol) study in patients undergoing

• smoking cessation

• Completion of enrolment of NIH-funded phase 2 study of INV102 (nadolol) in asthma patients

==> picture [98 x 41] intentionally omitted <==

29

==> picture [227 x 96] intentionally omitted <==

Dr Greg Collier Managing Director and CEO Invion Limited

c/- McCullough Robertson Lawyers, Level 11, 66 Eagle Street Brisbane, QLD, 4000 Australia P: +61 7 3295 0500

E: greg.collier@inviongroup.com W: www.inviongroup.com